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Abstract
Introduction: The management of locally advanced inoperable malignant thymoma is difficult as
there are no large randomized clinical trial data to guide treatment. However various case series
have shown that malignant thymoma is often a chemosensitive disease. Cisplatin-based
chemotherapy has been the gold-standard in the management of these patients. However when
thymic cancers are complicated by paraneoplastic syndromes that damage kidney and neurological
function, cisplatin use is often contraindicated.
Case presentation: We report a case of a 37 year old man with locally advanced malignant
thymoma complicated by significant nephrotic syndrome and renal impairment. He responded to a
novel combination of carboplatin, epirubicin and cyclophosphamide chemotherapy used as first line
therapy.
Conclusion:  The treatment with chemotherapy of locally advanced malignant thymoma
complicated by nephrotic syndrome and renal impairment is difficult due to the increase of toxicity.
In this case, a novel chemotherapy combination with lesser toxicity was used successfully. In
addition this chemotherapy combination did not impede the later use of conventional cisplatin-
based chemotherapy. Therefore we suggest a course of carboplatin-based chemotherapy for locally
advanced malignant thymoma in patients who are unsuitable for cisplatin.
Introduction
The management of locally advanced inoperable malig-
nant thymoma is difficult. There is no large randomized
clinical trial data to guide treatment. However various
case series have shown that malignant thymoma is often
a chemosensitive disease. Chemotherapy can be used neo-
adjuvantly to downstage disease rendering inoperable dis-
ease operable or as palliative treatment to extend life and
improve its quality. In 1993, Berruti et al used doxoru-
bicin, cisplatin, vincristine and cyclophosphamide neoad-
juvantly[1]. Hosokawa et al used a combination of
cisplatin, vincristine, doxorubicin and etoposide to render
an inoperable invasive thymoma operable[2]. Many case
series have reported >50% response rates with cisplatin-
based chemotherapy and this has now become the stand-
ard of care for inoperable or metastatic malignant thymo-
mas[3].
However not all patients are suitable for cisplatin-based
chemotherapy. In particular, patients with renal or neuro-
logical impairment are not suited to the renal and neuro-
toxicities of cisplatin. This is particularly pertinent as thy-
momas may present with associated renal impairment
and up to 35% have associated myasthenia gravis[4].
Published: 19 March 2008
Journal of Medical Case Reports 2008, 2:89 doi:10.1186/1752-1947-2-89
Received: 12 September 2007
Accepted: 19 March 2008
This article is available from: http://www.jmedicalcasereports.com/content/2/1/89
© 2008 Teoh and El-Modir; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Medical Case Reports 2008, 2:89 http://www.jmedicalcasereports.com/content/2/1/89
Page 2 of 4
(page number not for citation purposes)
In this case report, we describe a challenging case of recur-
rent locally advanced malignant thymoma complicated
by renal impairment and nephrotic syndrome. In view of
this, the less nephrotoxic platinum – carboplatin was
used. We describe our experience with carboplatin in
combination with epirubicin, cyclophosphamide chemo-
therapy which to our knowledge is a yet untested combi-
nation in the primary treatment of locally advanced
inoperable thymoma.
Case presentation
We report a case of a 37 year old man of Indian ethnicity
who had a thymectomy 16 years ago, in Oct 1989. He had
presented with myasthenia gravis. Perioperatively the
tumour was found to be adherent to the pericardium, left
phrenic nerve, anterior chest wall and the left lung. A com-
plete resection was reported and he did not receive chem-
otherapy or adjuvant radiotherapy at that time.
Apart from mild myasthenic symptoms managed with
pyridostigmine, he had been well until early 2005 when
he developed new left sided chest pain. CT scan of the tho-
rax from March 2005 showed extensive involvement of
the pleura on the left side with penetration of the dia-
phragm and invasion of the spleen (Masouka Stage IVA).
The tumour was also wrapping around the aortic arch. He
underwent an exploratory left thoracotomy in May 2005,
but unfortunately surgical debulking was not possible and
pleural biopsies were taken. The histology report was of a
recurrent well differentiated thymic carcinoma (Fig. 1).
Postoperatively he developed acute renal impairment and
peripheral oedema. A renal biopsy in May 2005 con-
firmed minimal change nephropathy (Fig. 2). His renal
impairment may have also been made worse by a degree
of acute tubular necrosis post-operatively. At this stage his
serum creatinine was 172 umol/L with a creatine clear-
ance of 42 ml/min and he had significant proteinuria of
24 g/L with a serum albumin of 15 g/L. His WHO per-
formance status was 1. He was therefore started on pred-
nisolone 40 mg daily as initial treatment for his nephrotic
syndrome and was subsequently referred for chemother-
apy.
Due to his renal dysfunction and proteinuria, he was ini-
tially commenced in June 2005 on epirubicin and cyclo-
phosphamide (EC) chemotherapy at reduced doses of
37.5 mg/m2 and 300 mg/m2  respectively. Cycles were
repeated every 3 weeks. 2nd and subsequent cycles were
given at full doses of 70 mg/m2 and 600 mg/m2.
After 2 cycles of chemotherapy and 2 months treatment
with prednisolone 40 mg daily, his nephropathy
improved to a serum creatinine of 63 umol/L, serum albu-
min of 25 g/L and his proteinuria to under 6 g/L. This
allowed for the addition of a platinum chemotherapy
agent and for his steroid dose to be gradually tapered by
approximately 5 mg every 2 weeks. In view of his recent
nephropathy and ongoing proteinuria – carboplatin was
chosen over cisplatin. The initial carboplatin dose was
AUC 3.5 (calculated using the Calvert formula) and this
was increased to AUC 4 and subsequently to AUC 5 in the
following 4 cycles of carboplatin combination chemo-
therapy. He tolerated treatment extremely well and his
renal function remained in the normal range throughout
these 4 cycles. On completion of the 6 cycles of chemo-
therapy his serum creatinine was 81 umol/L, serum albu-
min 39 g/L and proteinuria 0.34 g/L.
Electron microscopy demonstrating minimal change neph- ropathy Figure 2
Electron microscopy demonstrating minimal change 
nephropathy.
Haematoxylin and eosin stains from biopsy of the thymic  tumour Figure 1
Haematoxylin and eosin stains from biopsy of the 
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He had one admission to hospital due to epigastric pain
and vomiting prior to his 2nd cycle of chemotherapy. This
may have been brought on by the combination of chem-
otherapy and high dose steroids. This promptly settled on
high dose omeprazole. He also had grade 1 joint aches
and a bursitis of the left elbow which settled on oral anti-
biotics.
A CT scan in October 2005, 2 weeks after his 6th and last
cycle of chemotherapy, showed a good partial response in
comparison with scans taken pre-chemotherapy (Fig. 3).
He remained symptom-free and without disease progres-
sion until February 2006. Time to progression was 4
months. He went on to receive 2nd line chemotherapy in
the form of etoposide, ifosfamide and cisplatin chemo-
therapy for a further 6 cycles. His minimal change neph-
ropathy remained in remission at this time allowing for
the safe introduction of cisplatin. He attained a good par-
tial response again from this regime but subsequently pro-
gressed again in April 2007. He remains alive and
independent at the time of submission of this report.
Conclusion
Thymic tumours may rarely be complicated by nephrotic
syndrome at the time of initial diagnosis, on recurrence or
even in remission[5]. The cellular pathology linking these
two conditions have yet to be fully explained, although T-
cell dysfunction has been suggested[5]. The vast majority
of nephrotic syndrome cases associated with thymic
tumours are due to minimal change nephropathy – and
the mainstay of treatment is with high dose steroids and
treatment of the primary tumour.
However chemotherapy treatment of thymic tumours
complicated by nephrotic syndrome requires special con-
sideration. Nephrotic syndrome confers an increased risk
of infection due to the lost of immunoglobulins. Thus the
risk of neutropaenic sepsis with chemotherapy is greater.
In this case, we managed the risk of neutropaenic infec-
tion by gradually titrating the dose upwards as the pro-
teinuria improved and treating any signs of infection
without delay.
Classically cisplatin-based chemotherapy has been used
in the treatment of locally advanced or metastatic malig-
nant thymoma. Hanna et al at Indiana University did use
high-dose carboplatin (700 mg/m2) with etoposide in
patients with recurrent thymoma but in association with
peripheral blood stem cell rescue[6]. Jan et al reported a
case of recurrent thymoma in which carboplatin and pacl-
itaxel chemotherapy was used in the 2nd line setting
which resulted in an improvement of clinical symptoms
and reduction in the tumour mass[7]. The authors sug-
gested further investigation on the use of carboplatin in
the 1st line setting.
To our knowledge carboplatin has not been used in the 1st
line treatment of locally advanced or recurrent thymoma.
The advantage of carboplatin over cisplatin is its lesser
nephrotoxicity and neurotoxicity. These characteristics are
particularly useful as thymomas are frequently associated
with paraneoplastic syndromes which often affect renal
and/or neurological function as demonstrated in this
case[4]. This case also demonstrates that carboplatin use
Pre- and post-treatment CT scans at the level of the carina Figure 3
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upfront did not impede the subsequent responsiveness of
the tumour to cisplatin-based chemotherapy.
Doxorubicin has also been the anthracycline of choice in
most other reported cases of chemotherapy for malignant
thymomas. Macchiarini et al used epirubicin in combina-
tion with cisplatin and etoposide but in the neoadjuvant
setting[8]. As epirubicin may be less cardio-toxic com-
pared with doxorubicin, it may be a better choice espe-
cially if thoracic radiotherapy will be or had been used
previously. In addition, cyclophosphamide was used ini-
tially rather than ifosfamide. Ifosfamide was not used ini-
tially as his low serum albumin would have increased the
risk of ifosfamide-induced encephalopathy. Furthermore
steroid-resistant nephrotic syndrome has been shown to
respond to cyclophosphamide and therefore it may have
had a dual benefit of treating both nephropathy and
tumour in this case[9].
Locally advanced inoperable malignant thymoma com-
plicated by nephrotic syndrome presents a challenge to
conventional treatment. Although this is usually a chem-
osensitive tumour, the toxicity of traditional agents such
as cisplatin may prohibit their use. Can carboplatin there-
fore be considered an equivalent alternative to cisplatin in
the chemotherapy treatment of thymic cancers? In the
treatment of ovarian or small cell lung cancer, carboplatin
has been shown to be broadly equivalent to cisplatin.
Conversely in the treatment of germ cell tumours it has
been shown to be clearly inferior[10]. The above case
demonstrates that carboplatin-based chemotherapy has
activity against locally advanced inoperable thymic can-
cers in the 1st line setting. In patients who have renal or
neurological impairment, we suggest that carboplatin
would be the better alternative. However in those who
could tolerate cisplatin, a head-to-head clinical trial
would be needed, but may be difficult due to the relative
rarity of thymic cancers. In the absence of strong clinical
data, we suggest a course of carboplatin-based chemother-
apy for locally advanced malignant thymoma in patients
who are unsuitable for cisplatin.
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